https://www.zacks.com/stock/news/2236362/gritstone-bio-inc-grts-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2236362
Mar 05, 2024 - Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 27.78% and 116.31%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
zc:-5245180333520481714
0
https://www.zacks.com/stock/news/2233203/is-adicet-bio-acet-stock-outpacing-its-medical-peers-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2233203
Feb 28, 2024 - Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
zc:3582681149084114504
0
https://www.zacks.com/stock/news/2224777/is-adicet-bio-acet-outperforming-other-medical-stocks-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2224777
Feb 12, 2024 - Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
zc:3152561133538274283
0
https://www.zacks.com/stock/news/2221181/bio-rad-laboratories-bio-to-post-q4-earnings-what-awaits?cid=CS-ZC-FT-analyst_blog|earnings_preview-2221181
Feb 05, 2024 - Ongoing weakness in the biopharma end markets, impacting the sales of Life Science tools and bioprocessing products, are likely to have impeded Bio-Rad's (BIO) Q4 revenues.
zc:-3836222881949672549
0
https://www.rttnews.com/story.aspx?Id=3421577
Feb 02, 2024 - Medical technology company Intelligent Bio Solutions Inc. (INBS), Friday announced that it expects higher revenue for its second quarter. The preliminary outlook is mainly due to increased demand for its drug screening solution, and expansion into new global markets.
0
rttnews:-927945599518664655
0
https://seekingalpha.com/news/4061494-spac-semper-paratus-shareholders-okay-merger-with-tevogen-bio?source=feed_sector_healthcare
Feb 01, 2024 - SPAC Semper Paratus Acquisition Corp. (LGST) shareholders have approved a merger deal with immunotherapy developer Tevogen Bio (TVGN). Read more here.
0
sa:-9050644345498336940
0
https://seekingalpha.com/news/4061462-tourmaline-bio-director-discloses-purchase-of-stake-worth-325m?source=feed_sector_healthcare
Feb 01, 2024 - This article discusses insider trading at Tourmaline Bio (TRML), with its director Mark McDade acquiring 100,000 company shares for $3.25 million.
0
sa:-1005409249916418125
0
https://www.zacks.com/stock/news/2218877/2seventy-bio-tsvt-divests-r-d-assets-to-regeneron-stock-up?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2218877
Jan 31, 2024 - 2seventy bio (TSVT) inks an asset purchase agreement with Regeneron to sell its oncology and autoimmune pipeline to the latter.
zc:6104452854925000797
0
https://seekingalpha.com/news/4058138-tourmaline-bio-looks-to-raise-cash-through-a-public-offering?source=feed_sector_healthcare
Jan 24, 2024 - Tourmaline Bio announces proposed public offering of common stock. Underwriters may purchase additional shares.
0
sa:-6838828924459981455
0
https://seekingalpha.com/news/4057908-annovis-bio-kura-oncology-among-other-healthcare-movers?source=feed_sector_healthcare
Jan 24, 2024 - Read about the top gainers and losers in the healthcare sector.
0
sa:-6695813229733944057
0